LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Remote Patient Monitoring Wins AAHKS’s 2023 Innovation Award
Company News

Remote Patient Monitoring Wins AAHKS’s 2023 Innovation Award

December 7, 2023 2 min read Premium comments

Advertisement

Remote Patient Monitoring Wins AAHKS’s 2023 Innovation Award
Courtesy of Force Therapeutics LLC
#hiparthroplasty#kneearthroplastySecondary#industryinnovationaward

Remote patient monitoring, one of the great promises of the digital revolution in medicine, was chosen from a field of 16 submissions and won the prestigious Industry Innovation Award by the American Association of Hip and Knee Surgeons (AAHKS) at the organization’s recent annual meeting in Dallas, Texas.

The company that developed this digital technology, 13-year-old, New York City-based Force Therapeutics LLC, was founded by a former physical therapist with more than 20 years of clinical physical therapy experience. The founder, Bronwyn Spira, understood the challenges for patients who had been sent home with vague care instructions and stick figure drawings, but ended up struggling with recovery at home. Her belief, and it is the reason she founded Force Therapeutics, is that empowering patients with the right education and communication can take a lot of cost out of the system and, most importantly, improve patient outcomes.

Amen.

“AAHKS is truly excited to grant the Industry Innovation Award to Force Therapeutics for its addition of Remote Therapeutic Monitoring (RTM) to its digital care platform. It’s very important for industry to have a role in developing innovations in patient care and with 16 entries submitted, I think that’s a great indicator for innovation in the field of hip and knee arthroplasty,” said Javad Parvizi, M.D., FRCS, AAHKS President.

Company CEO Bronwyn Spira told OTW, “At Force Therapeutics, our mission is to improve patient outcomes and provider efficiency while reducing the overall cost of care.”

“As the leading MSK patient engagement platform, Force Therapeutics is uniquely equipped to optimize digital care and RTM reimbursement, resulting in strong patient outcomes and satisfaction, while reducing costly barriers, improving access to care and optimizing provider workflows.”

“The 2023 AAHKS Industry Innovation Award is validation that our advanced platform innovations continue to provide high quality improvements for both patients and surgeons and is in sync with what the Orthopedic market needs.”

“Our RTM solution allows health systems, physician practices, and ambulatory surgical centers to provide patients with virtual physical therapy and remote monitoring that adheres to CMS [Centers for Medicare and Medicaid Services] guidelines. Our provider-prescribed digital care management platform is validated to provide compliant documentation for the new RTM Current Procedural Terminology (CPT) codes finalized by the Centers for Medicare and Medicaid Services,” added Spira.

Advertisement

“It is a powerful tool, with deep clinical intelligence, that scales workflows and maximizes care teams to drastically improve efficiency, profitability, and set a new standard of high-quality care.”

Finally, said Spira, “Our system engages both patients and providers, enabling robust real-time data collection and actionable insights to produce the most effective patient care and the most efficient provider workflows possible. By automating routine touch points and tasks, Force Therapeutics enables clinical care teams to intelligently monitor and interact with patients throughout their care journey.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy